N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.65p
   
  • Change Today:
    -0.025p
  • 52 Week High: 3.07p
  • 52 Week Low: 0.60p
  • Currency: UK Pounds
  • Shares Issued: 268.78m
  • Volume: 1,668,891
  • Market Cap: £1.75m

Deal with Barclays    Trade now with Barclays Stockbrokers

N4 Pharma shares surge on latest from Nanomerics collaboration

By Josh White

Date: Thursday 03 Dec 2020

LONDON (ShareCast) - (Sharecast News) - Specialist pharmaceuticals company N4 Pharma updated the market on its ongoing research collaboration agreement with Nanomerics on Thursday.
The AIM-traded firm had initiated the first phase of research to test the stability of different formulations of 'Nuvec' loaded with a well-characterised plasmid DNA, as it announced in February.

It reported on Thursday that, in addition to not degrading the plasmid DNA, Nuvec formulations that had been freeze dried and stored for 14 days either at room temperature or at four degrees Celsius, showed "no significant drop" in in-vitro transfection capability following reconstitution compared to fresh formulations.

In parallel to continued work on analysing stability duration, N4 said different formulations would now be chosen to move forward into the second phase of the work programme, testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model.

"Demonstrating that Nuvec® loaded with a plasmid DNA can be dried, stored at convenient temperatures and reconstituted without any drop in transfection is a significant step forward in our formulation development work," said chief executive officer Nigel Theobald.

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines.

"However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions."

Theobald said that, although vaccine efficacy was primarily determined by the selected nucleic acid antigen, having a stable, easy-to-store and easy-to-use vaccine was "crucial" in helping vaccine acceptance and uptake.

"A formulation stable at room temperature or even refrigerated can represent significant cost savings in vaccine transportation, storage and administration.

"We believe, to the extent that Nuvec as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers.

"Work will continue in this area and will add to the breadth of proof of concept data we are building for the use of Nuvec® as a delivery system for vaccines and cancer treatments."

At 1237 GMT, shares in N4 Pharma were up 40% at 8.4p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.65p
Change Today -0.025p
% Change -3.70 %
52 Week High 3.07p
52 Week Low 0.60p
Volume 1,668,891
Shares Issued 268.78m
Market Cap £1.75m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Value
8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average8.47% above the market average
14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average14.81% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:20 1,428 @ 0.70p
16:20 344,883 @ 0.64p
16:14 160,623 @ 0.64p
15:46 1,000 @ 0.60p
15:40 700 @ 0.60p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page